PMN (ProMIS Neurosciences) Beta: -0.7855 (As of Jun. 30, 2026)


PMN ProMIS Neurosciences Inc PMN
30 GF Score
Price $13.39
! 2 Warning Signs
View Full Analysis

What is ProMIS Neurosciences Beta?

ProMIS Neurosciences PMN +22.42% 30 Beta is -0.7855 as of Jun. 30, 2026. GuruFocus rates PMN with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-30), ProMIS Neurosciences's Beta is -0.7855.


ProMIS Neurosciences  (NAS:PMN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


ProMIS Neurosciences Beta Related Terms


ProMIS Neurosciences Beta Historical Data

* Premium members only.

The historical data trend for ProMIS Neurosciences's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProMIS Neurosciences Beta Chart

ProMIS Neurosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 0.98 0.10 -0.51 -0.68

ProMIS Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -0.45 -0.34 -0.68 -0.34

PMN vs BMEA, ANIX, ATRA: Beta Comparison

For the Biotechnology subindustry, ProMIS Neurosciences's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProMIS Neurosciences Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Beta distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's Beta falls into.


PMN
30GF Score
ProMIS Neurosciences Inc PMN
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProMIS Neurosciences Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.7855 mean?
ProMIS Neurosciences (PMN) has a Beta of -0.7855 as of Jun. 30, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for ProMIS Neurosciences and its competitors.
Is ProMIS Neurosciences' Beta too high?
ProMIS Neurosciences' current Beta is -0.7855. Overall, ProMIS Neurosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' Beta compare to BMEA and ANIX?
ProMIS Neurosciences' Beta of -0.7855 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for ProMIS Neurosciences and its competitors. ProMIS Neurosciences's current Beta is -0.7855. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current Beta of -0.7855. The current Beta is -0.7855. ProMIS Neurosciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current Beta is -0.7855 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProMIS Neurosciences Business Description

Other Exchanges 23J:Germany
Address 1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
30GF Score

Get the complete analysis for PMN

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.39
Price